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ABSTRACT
OBJECTIVE: Trace the pattern of drug use during delivery hospitalization.
METHOD: Cross-sectional study carried out from June to October 2015, included in the 2015 
Pelotas births cohort. All women living in the urban area of the city who were hospitalized for 
delivery were part of the sample. We collected information regarding drug prescription and 
drug use by mothers during the whole period of hospitalization. Sociodemographic data were 
obtained in interview after delivery, and other data were obtained from medical charts. The 
drugs were classified according to the Anatomical Therapeutic Chemical system.
RESULTS: All study participants (1,392 women) used at least one drug, with the mean amount 
being larger the higher the age of the mother, both prepartum/during delivery and postpartum. 
It was also higher in cases of spinal anesthesia or general anesthesia, cesarean deliveries, school 
hospitals, and longer hospitalizations. Analysis of the sample as a whole showed no significant 
difference in the number of drugs used according to hospitalization type, but when stratified 
by length of hospital stay the mean was higher in SUS hospitalizations than in private and 
health insurance hospitalizations. Drugs for the nervous system were the most used (30.5%), 
followed by drugs for the alimentary tract and metabolism (13.8%). The use of anti-infective 
agents and drugs that act on the cardiovascular and respiratory systems was higher in mothers 
who underwent cesarean delivery. This study showed high drug consumption in the delivery 
hospitalization period, and showed cesarean delivery and epidural anesthesia as the main 
factors related to high drug consumption in this period.
CONCLUSIONS: We found high drug consumption in the delivery hospitalization period, 
and the main factors were cesarean delivery and epidural anesthesia. Drugs that act on the 
nervous system were the most used.
DESCRIPTORS: Parturition. Midwifery. Perinatal Care. Drug Utilization. Risk Factors. 
Socioeconomic Factors. 
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INTRODUCTION
Drug use in hospitals is highly prevalent, independently of health problem or hospital 
sector. During delivery hospitalization, drugs are used to induce labor, reduce pain, or treat 
preexisting maternal diseases that require maintenance of pharmacological control. The use 
of these drugs, although clinically justified, may affect the health of the newborn. In all cases, 
the choice of drug should include evaluation of safety of use during the gestation period1,2.
In recent years some researches were conducted in developed countries using large databases 
or national administrative records, which have been increasingly used in the field of perinatal 
pharmacoepidemiology to attempt to address the deficiency of clinical epidemiological 
studies on pregnant women3–7. However, Brazil lacks pharmacoepidemiological databases 
to conduct studies with such objective.
The characterization of drug prescription during delivery hospitalization has been little 
investigated, in comparison with drug use throughout gestation8,9. This difference may be 
explained, in part, by the higher importance attributed to the teratogenic risks of drugs8. 
A study conducted in a maternity hospital of Minas Gerais analyzed all drug prescriptions 
during one year, but comprising prescriptions of all hospitalizations of the maternity 
hospital and not only those of women admitted for delivery10. Another study conducted 
in a maternity hospital of Ceará evaluated drug use in the immediate postpartum period 
and 15 days after hospital discharge, but not the entire delivery hospitalization period11.
Drug use in this period may also have undesired effects on the newborn, such as respiratory 
depression9,12. In addition, analysis of drug use between different health care services 
(for example, between public and private maternity hospitals) may show differences 
in therapeutic conducts. Investigating the improper use of certain drugs, such as the 
indiscriminate use of oxytocin in labor, may show irrational practices in the employment 
of drugs13.
This study aimed to characterize the pattern of drug use during delivery hospitalization. 
METHODS
Cross-sectional study carried out from June 5 to October 5, 2015, included in the 2015 
Pelotas births cohort (C2015). The sample comprised all women living in the urban 
area of the city of Pelotas, state of Rio Grande do Sul, colônia Z3 and Jardim América 
neighborhood of the municipality of Capão do Leão who were hospitalized for delivery 
in the five hospitals of the city in the study period, regardless of whether the childbirth 
resulted in stillborn or born alive. More details on the perinatal study of C2015 can be 
found in the methodological article14.
We collected information regarding drug prescription and drug use by mothers during 
the whole hospitalization period. We obtained sociodemographic data of the mothers 
in interview conducted shortly after childbirth, still in hospital, by previously trained 
interviewers of the cohort. We analyzed the following variables: age (collected in full 
years and categorized into the 13–19, 20–30, and 31–45 ranges), economic classification 
according to the criteria of the Brazilian Association of Survey Companies15 (A, B, C, 
or D+E); self-reported skin color (white, black, or brown – which includes dark, brown, and 
indigenous), and educational level (collected in years of continuous study and categorized 
into the 0–4, 5–8, 9–11, or ≥ 12 ranges).
The other data were collected from medical charts, soon after hospital discharge, 
by previously trained Pharmacy students and nursing technicians. We registered the 
following information: hospital of birth, anesthesia type (spinal, epidural, topical, general, 
or none), delivery type (vaginal or caesarian delivery), and hospitalization type (Unified 
Health System – SUS, health insurance plan, or private health care). The variables for 
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hospitalization days, hospitalization days before delivery, and hospitalization days after 
delivery were based on the dates of admission, delivery, and discharge.
As for the drugs used, we obtained information on the drug name, time of use 
(prepartum/during delivery or postpartum), and days of use. We used the International 
classification Anatomical Therapeutic Chemical (ATC) of the World Health Organization16 to 
classify them by therapeutic groups to the fifth level, when possible. In order not to identify 
the hospitals, they were named with the letters from A to E, with A and C being medical 
school hospitals.
The information was typed directly on a tablet and later transferred to the computer, 
and the data were analyzed with the statistical package Stata version 12.0 (Stata Corp., 
College Station, USA). In the descriptive analysis, we used the analysis of variance (ANOVA) 
to evaluate possible associations between the mean and standard deviation (SD) of the 
number of drugs used in each category of exposure variables (mothers being analysis 
units). To analyze the distribution of the most used drugs according to therapeutic group 
and delivery type, anesthesia type, mother age, and birth hospital, we used the bank in the 
long format, considering the drug as analysis unit. For these analyses we estimated the 
prevalence and the 95% confidence intervals.
The project was approved by the Research Ethics Committee of the Medical School of the 
Federal University of Pelotas, under number 315,264, including only pregnant women who 
agreed to participate in the study and signed the informed consent form.
RESULTS
1,392 women participated in the study of the 4,270 who were part of the 2015 perinatal 
cohort study. The mean age was 27 years (SD = 6.7; minimum = 13; maximum = 45). Most of 
the sample (65.9%) had nine or more years of formal education and belonged to economic 
class C (48.7%). Only five declared being indigenous, and the same number as having yellow 
skin color, being grouped with those who declared having dark or brown skin (13.2%); 70.0% 
declared having white skin color (Table 1). The distribution of this sample, in relation to 
the sociodemographic variables presented, was similar to the total of the cohort (p > 0.05). 
Medical school hospitals totaled more than 50% of deliveries.
The most used anesthesia was spinal anesthesia (66.7%), classification into which a woman 
who received epidural anesthesia was also grouped. General anesthesia was used in four 
mothers (0.3%) due to complications during delivery. The predominant delivery type was 
caesarean delivery (66.8%), as shown in Table 1. Only 2 of the 462 women who had vaginal 
delivery were given spinal anesthesia; 339 women were given topical anesthesia; and 118 
were given none.
Analysis of the association between hospital and delivery type shows statistically significant 
difference, especially as to the hospital that exclusively serves the SUS and to the two 
hospitals that exclusively serve private health care and health insurance. The other two 
hospitals are mixed, serving both the SUS and private health care and health insurance. 
The exclusively SUS hospital held 22.7% (95%CI 18.9–26.6) of all vaginal deliveries and 14.8% 
(95%CI 12.5–17.1) of caesarean deliveries. The exclusively private hospitals held 2.0% (95%CI 
0.7–3.2) of vaginal deliveries and 14.1% (95%CI 11.8–16.3) of cesarean deliveries, while mixed 
hospitals held 42.2% (95%CI 37.7–46.7) and 33.1% (95%CI 28.8–37.4) vaginal deliveries and 
32.3% (95%CI 29.2–35.2) and 38.8% (95%CI 35.6–42.0) of caesarean deliveries.
Mean hospitalization time was 3.6 days (SD=4.0), median of two days (interquartile 
range – IQR25-75 2–4). After delivery, mean hospitalization time was 2.7 days (SD = 2.2), 
median of two days (IQR25-75 2–4). We found no statistically significant difference in mean 
hospitalization days according to delivery type (3.6 days for vaginal delivery and 3.5 days 
for cesarean delivery), but we found statistically significant difference in the association 
4Drug use in delivery hospitalization Silveira MPT et al.
https://doi.org/10.11606/S1518-8787.2019053000913
Table 1. Description of sample and mean number of drugs used during delivery hospitalization according 
to sociodemographic variables and hospitalization characteristics. 2015 Pelotas Births Cohort (June to 
October), Brazil.
Variable
Sample Mean number of drugsa
n (%)
All
Prepartum/
during delivery
Postpartum
Mean (SD) Mean (SD) Mean (SD)
Age (years) p = 0.0004 p ≤ 0.001 p = 0.041
13–19 211 (15.2) 9.98 (4.9) 6.5 (4.3) 5.3 (2.4)
20–30 742 (53.3) 10.1 (4.4) 6.7 (3.9) 5.4 (2.2)
31–45 439 (31.6) 11.0 (4.3) 7.6 (3.9) 5.7 (2.3)
Skin colorb p = 0.643 p = 0.078 p = 0.230
White 975 (70.0) 10.4 (4.3) 7.0 (3.8) 5.4 (2.1)
Black 232 (16.7) 10.1 (4.9) 6.4 (4.3) 5.7 (2.5)
Brownc 183 (13.2) 10.4 (4.9) 7.0 (4.3) 5.6 (2.6)
Educational level of mother (complete years 
of formal education)
p = 0.243 p = 0.011 p = 0.106
0–4 119 (8.6) 9.6 (5.6) 6.3 (5.0) 5.4 (2.3)
5–8 355 (25.4) 10.2 (4.7) 6.6 (4.2) 5.7 (2.3)
9–11 472 (33.9) 10.4 (4.6) 6.9 (4.2) 5.6 (2.3)
12 or more 446 (32.0) 10.5 (3.7) 7.4 (3.1) 5.3 (2.1)
Economy class (ABEP)d p = 0.485 p = 0.202 p = 0.08
A 51 (3.8) 11.2 (2.9) 7.8 (2.5) 5.7 (2.1)
B 375 (27.9) 10.3 (3.4) 7.1 (3.0) 5.3 (2.1)
C 654 (48.7) 10.3 (4.7) 6.8 (4.1) 5.6 (2.3)
D+E 262 (19.5) 10.2 (5.2) 6.8 (4.8) 5.5 (2.3)
Hospital of birth p ≤ 0.001 p ≤ 0.001 p ≤ 0.001
A 514 (36.9) 10.3 (4.1) 6.5 (3.4) 5.7 (2.2)
B 496 (35.6) 9.7 (3.8) 6.2 (3.2) 5.5 (2.1)
C 243 (17.5) 12.0 (6.5) 8.8 (6.1) 6.0 (2.6)
D 126 (9.1) 9.8 (2.4) 7.9 (2.2) 3.9 (1.2)
E 14 (1.0) 9.7 (3.3) 7.7 (2.3) 4.4 (2.3)
Type of anesthesia p ≤ 0.001 p ≤ 0.001 p ≤ 0.001
Spinal anesthesiae 929 (66.7) 12.6 (3.5) 8.8 (3.2) 6.3 (2.2)
Topical anesthesia 341 (24.5) 5.9 (1.9) 3.2 (1.6) 3.9 (1.4)
General anesthesia 4 (0.3) 13.3 (7.1) 11.3 (6.8) 3.0 (2.2)
None 118 (8.5) 5.6 (2.7) 2.7 (2.6) 4.0 (1.7)
Type of delivery p ≤ 0.001 p ≤ 0.001 p ≤ 0.001
Vaginal delivery 462 (33.2) 5.8 (2.2) 3.1 (2.0) 4.0 (1.5)
Cesarean delivery 930 (66.8) 12.6 (3.6) 8.8 (3.2) 6.3 (2.1)
Type of hospitalizationf p = 0.927 p = 0.002 p ≤ 0.001
Unified Health System (SUS) 884 (66.4) 10.3 (5.0) 6.6 (4.5) 5.6 (2.3)
Health insurance plan 304 (22.8) 10.3 (2.8) 7.5 (2.5) 5.0 (1.9)
Private health care 143 (10.7) 10.4 (2.6) 7.2 (2.3) 5.3 (1.8)
Days of hospitalization p ≤ 0.001 p ≤ 0.001 p ≤ 0.001
Up to 1 217 (15.6) 9.4 (2.8) 7.1 (2.6) 4.4 (1.7)
2 489 (35.1) 9.5 (3.6) 6.2 (3.1) 5.2 (1.9)
3 313 (22.4) 9.4 (4.0) 5.9 (3.5) 5.4 (1.9)
4 to 10 315 (22.6) 12.1 (5.5) 7.9 (4.9) 6.5 (2.6)
11 or more 58 (4.2) 16.0 (5.5) 12.7 (4.9) 7.3 (3.2)
Days of hospitalization before delivery p ≤ 0.001 p ≤ 0.001 p ≤ 0.001
Up to 1 1.243 (89.3) 9.8 (4.1) 6.4 (3.5) 5.3 (2.1)
Continue
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between hospitalization days and hospitalization type (p < 0.001). The extremes of 
1-day hospitalization and 4–10-day hospitalization period are especially interesting. 
For SUS hospitalization, the ratio of women with 1-day hospitalization was only 0.5% 
(95%CI 0.09–0.8); for private health care and health insurance hospitalization, that ration 
was 36.4% (95%CI 28.3–44.3) and 48.3% (95%CI 42.7–54.0), respectively. The length of 
hospital stay was 4–10 days in 33.4% (95%CI 30.2–36.5) of SUS hospitalizations and in only 
1.4% (95%CI 0.5–3.3) and 2.9% (95%CI 1.0–4.8) of private health care and health insurance 
hospitalizations, respectively.
Description of mean and standard deviation of the number of drugs used during 
delivery hospitalization, according to exposure variables and hospitalization time 
(prepartum/during delivery or postpartum), is found in Table 1. All women were given 
at least one drug, and the mean number was significantly higher the higher the age of 
the mother, both at prepartum/during delivery and postpartum. It was also significantly 
higher when spinal anesthesia or general anesthesia were used (in this case mainly at 
prepartum/during delivery), in cesarean deliveries, in medical school hospitals, and the 
higher the number of hospitalization days. We found no significant difference in the number 
of drugs used according to hospitalization type (SUS, health insurance, or private health 
care) when the entire sample was analyzed; however, when stratified by hospitalization 
period (prepartum/during delivery or postpartum), the mean number of drugs was 
significantly higher in SUS hospitalizations than in private health care and health insurance 
hospitalizations. We found no significant difference in the mean number of drugs used 
according to economic class (Table 1).
A total of 14,383 drugs were used. Table 2 shows the distribution of the most used drugs, 
classified according to the Anatomical Therapeutic Chemical system (levels 1 and 3). 
Drugs that act on the nervous system (ATC group N) were the most used (n = 4,274; 
30.5%), followed by those that act on the alimentary tract and metabolism (ATC group 
A; n = 1,932; 13.8%).
Table 3 shows the most used drugs that act on the nervous system, stratified by anesthesia 
type. For mothers given spinal anesthesia, the most frequent were bupivacaine (30.2%), 
morphine (23.8%), dipyrone/metamizole (18.5%), and paracetamol (12.0%). For mothers 
given only topical anesthesia (vaginal area), the most used drugs were paracetamol (53.5%) 
and bupivacaine (40.3%).
Table 1. Description of sample and mean number of drugs used during delivery hospitalization according to 
sociodemographic variables and hospitalization characteristics. 2015 Pelotas Births Cohort (June to October), 
Brazil. Continuation
2 46 (3.3) 12.8 (6.0) 9.2 (5.0) 6.5 (2.9)
3 25 (1.8) 14.1 (4.4) 10.2 (4.0) 6.8 (2.0)
4 to 10 53 (3.8) 15.9 (4.4) 12.2 (4.1) 7.7 (2.4)
11 or more 25 (1.8) 17.0 (4.7) 14.1 (4.5) 7.1 (2.7)
Days of hospitalization after delivery p ≤ 0.001 p ≤ 0.001 p ≤ 0.001
Up to 1 229 (16.5) 9.3 (2.8) 7.0 (2.6) 4.3 (1.7)
2 644 (46.3) 9.8 (3.9) 6.5 (3.5) 5.3 (1.9)
3 277 (19.9) 10.5 (4.4) 6.7 (4.0) 5.9 (2.0)
4 to 10 229 (16.5) 12.5 (6.1) 8.3 (5.6) 6.7 (2.9)
11 or more 13 (0.9) 13.9 (5.9) 9.4 (4.2) 7.6 (4.4)
Total 1,392 (100) 10.3 (4.5) 6.9 (4.0) 5.5 (2.2)
a Analysis of variance (ANOVA). 
b 2 missing (two mothers did not respond).
c Includes skin colors dark, brown and indigenous.
d Brazilian Association of Survey Companies (52 missing).
e Includes a case of epidural anesthesia.
f 51 missing (information about type of hospitalization was not found in the hospital records).
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The distribution of therapeutic groups according to delivery type (cesarean or vaginal 
delivery) is found in Table 4. Drugs that act on the nervous system, alimentary tract and 
metabolism, cardiovascular system and respiratory system, as well as anti-infective agents, 
were more used in mothers who had cesarean delivery than in those who had vaginal 
delivery. Greater emphasis should be given to anti-infective agents (1.6 times higher use) 
Table 2. Distribution of the drugs most used in hospitalization for delivery according to the Anatomical 
Therapeutic Chemical Classificationa (ATC; levels 1 and 3). 2015 Pelotas Births Cohort (June to 
October), Brazil.
Therapeutic groups n %
N – Nervous System 4,274 30.5
N02B – Other analgesics and antipyretics 1,483 10.6
N01B – Local anesthetics 1,316 9.4
N02A – Opioids 938 6.7
N01A – General anesthetics 188 1.3
N05A – Antipsychotics 152 1.1
Others 197 1.4
A – Alimentary tract and metabolism 1,932 13.8
A04A – Antiemetic and antinauseating agents 822 5.9
A03A – Drugs for functional disorders 633 4.5
A03F – Propulsive agents 262 1.9
Others 215 1.5
M – Musculoskeletal system 1,888 13.5
M01A – Anti-inflammatory and antirheumatic agents 1,871 13.4
Others 17 0.1
H – Hormonal preparations for systemic use 1,601 11.3
H01B – Hormones of the posterior lobe of the pituitary 1,357 9.7
H02A – Corticosteroids for systemic use 219 1.5
H03A – Thyroidal preparations 25 0.1
J – Anti-infective for systemic use 1,361 9.7
J01D – Other beta-lactam antibacterials 1,055 7.5
Others 306 2.2
B – Blood and blood-forming organs 1,009 7.3
B03A – Preparations containing iron 747 5.4
Others 262 1.9
C – Cardiovascular System 963 6.9
C01C – Cardiac stimulants – except glycosides 685 4.9
Others 278 2.0
R – Respiratory system 371 2.6
R06A – Antihistamines for systemic use 368 2.6
Others 3 0.03
D – Dermatologicals agents 347 2.5
D08A – Antiseptics and disinfectants 153 1.1
Others 194 1.4
G – Genitourinary system and sex hormones 195 1.4
G02A – Uterotonics 180 1.3
Others 15 0.1
Others 70 0.5
Total 14,011b 100
a World Health Organization, Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification 
and DDD assignment 2014. Oslo; 2014 [cited 2016 Mar 15]. Available from: whocc.no/atc_ddd_index/
b Of the 14,383 drugs used, 368 were not classified by the ATC system due to absence of reason for use, which 
may change the classification of the drug.
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Table 3. Distribution of the drugs that act on the nervous systema most used in hospitalization for delivery, 
stratified by type of anesthesiab. 2015 Pelotas Births Cohort (June to October), Brazil.
Drug
Spinal anesthesia Topical anesthesia 
n % 95%CI n % 95%CI
Bupivacaine 1,122 30.2 28.7–31.7 189 40.3 35.8–4.7
Morphine 887 23.8 22.5–25.2 1 0.2 -0.2–0.6
Dipyrone (metamizole) 686 18.5 17.2–19.7 25 5.3 3.2–7.3
Paracetamol 446 12.0 10.9–13.1 251 53.5 48.9–8.0
Phentanil 150 4.0 3.4–4.6 1 0.2 -0.2–0.6
Droperidol 144 3.9 3.2–4.5 - - -
Midazolam 142 3.8 3.2–4.4 - - -
Others 138 3.8 3 0.5
Total 3,715 100 469 100
a World Health Organization, Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC 
classification and DDD assignment 2014. Oslo; 2014 [cited 2016 Mar 15]. Available from: whocc.no/atc_ddd_
index/
b Stratification was held only for spinal anesthesia and topical anesthesia. Due to its very low frequency, general 
anesthesia was considered missing and epidural anesthesia was analyzed together with spinal anesthesia.
Table 4. Distribution of therapeutic groups used in delivery hospitalization according to the Anatomical Therapeutic Chemical Classificationa 
(ATC; level 1), stratified by delivery type. 2015 Pelotas Births Cohort (June to October), Brazil.
Therapeutic groupsb
Cesarean delivery Vaginal delivery
n % 95%CI n % 95%CI
N – Nervous System 3,720 32.8 31.9–33.6 554 20.7 19.1–22.2
N01BB01 – Bupivacaine 1,120 10.4 9.8–11.0 195 7.8 6.7–8.8
N02AA01 – Morphine 887 8.2 7.7–8.8 3 0.1 -0.01–0.2
N02BE01 – Paracetamol 446 4.2 3.7–4.5 313 12.5 11.2–13.8
A – Alimentary tract and metabolism 1,631 14.4 13.7–15.0 304 11.4 10.1–12.5
A04AA01 – Ondansetron 497 4.6 4.2–5.0 6 0.2 0.04–0.4
A03FA01 – Metoclopramide 202 1.9 1.6–2.1 50 2.0 1.4–2.5
A04AD51 – Association containing scopolamine 147 1.4 1.1–1.6 93 3.7 2.9–4.4
M – Musculoskeletal system 1,422 12.5 11.9–13.1 466 17.4 15.9–18.9
M01AE03 – Ketoprofen 916 8.6 8.0–9.0 43 1.7 1.2–2.2
M01AB05 – Diclofenac 488 4.5 4.1–5.0 423 17.0 15.4–18.4
J – Anti-infectives for systemic use 1,224 10.8 10.2–11.3 137 5.1 4.2–5.9
J01DB03 – Cephalothin 897 8.3 7.8–8.9 12 0.5 0.2–0.7
J06BB01 – Anti-D immunoglobulin (Rh) 71 0.7 0.5–0.9 36 1.4 0.9–1.9
H – Systemic Hormonal preparations 1,142 10.1 9.5–10.6 459 17.2 15.7–18.5
H01BB02 – Oxytocin 924 8.6 8.1–9.1 433 16.2 15.8–18.8
C – Cardiovascular System 897 7.9 7.4–8.4 66 2.5 1.8–3.0
C01CA09 – Metaraminol 548 5.1 4.7–5.5 0 0
C01CA01 – Etilefrine 134 1.3 1.0–1.4 2 0.1 -0.3–1.9
B – Blood and blood-forming organs 551 4.9 4.4–5.2 458 17.1 15.6–18.5
B03AA07 – Ferrous sulfate 389 3.6 3.2–4.0 357 14.3 12.9–15.6
B05XA03 – Sodium chloride 126 1.1 0.9–1.3 3 0.1 0.001–0.02
R – Respiratory system 349 3.1 2.8–3.4 22 0.8 0.5–1.1
R06AA02 – Diphenhydramine 172 1.6 1.3–1.8 11 0.4 0.1–0.7
R06AD02 – Promethazine 171 1.6 1.3–1.8 11 0.4 0.1–0.7
D – Dermatologicals 220 1.9 1.6–2.1 128 4.8 3.9–5.5
Others 184 1.6 81 3.0
Total 11,340 100 2,702 100
a World Health Organization, Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2014. Oslo; 
2014 [cited 2016 Mar 15]. Available from: whocc.no/atc_ddd_index/
b Of the 14,383 drugs used, 368 were not classified by the ATC system due to absence of reason for use, which may change the classification of the drug.
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and drugs that act on the cardiovascular system and respiratory system, whose prevalence 
rates were more than double in mothers who had caesarean delivery compared with those 
who had vaginal delivery. Among the drugs for the nervous system, bupivacaine was 33% 
more used in mothers who had cesarean delivery and morphine was used only by them, 
with prevalence of 8.2%. In contrast, paracetamol was two times more used in mothers 
who had vaginal delivery (12.5%). As for anti-infective agents, cephalotin was the most used 
(8.3%) and used only in women who had cesarean delivery. Metaraminol was the most used 
drug that acts on the cardiovascular system (5.1%), used only by women who had cesarean 
delivery. For vaginal deliveries, compared with cesarean deliveries, the most frequent 
groups were those that act on the musculoskeletal system (1.4 times higher), systemic 
hormonal preparations (1.7 times higher), drugs that act on the blood and blood-forming 
organs (2.5 times higher), and dermatological drugs (1.5 times higher), as shown in Table 4. 
Ketoprofen was used only in women who had caesarean deliveries (8.6%); however, diclofenac 
was 2.8 times more used in women who had vaginal delivery (17.0%, compared with 4.5% for 
cesarean deliveries). As for systemic hormonal preparations, oxytocin is highlighted, used 
in 8.6% of mothers who had caesarean delivery and in 16.2% of mothers who had vaginal 
delivery. Ferrous sulfate was three times more used in mothers who had vaginal delivery 
(14.3%, compared with 3.6% for cesarean deliveries). The prevalence rates of the drugs are 
not presented in the table.
Table 5 shows the distribution of therapeutic groups according to mother age. As for those 
that act on the musculoskeletal system and on the blood and blood-forming organs, the 
greater the age, the lower the prevalence of use, while for those that act on the cardiovascular 
system, the greater the age, the greater the use. Considering the musculoskeletal system, 
diclofenac and ketoprofen were the most used drugs; for diclofenac, the younger the mothers, 
the greater the use, while the opposite occurred with ketoprofen (data not presented in the 
table). In the therapeutic group of drugs that act on the blood and blood-forming organs, 
ferrous sulfate was the most used, and the younger the mothers, the greater the use. In the 
group of drugs that act on the cardiovascular system, metaraminol was the most used drug, 
but with no significant difference according to age group (data not presented in the table).
DISCUSSION
This study highlights the high drug use in mothers in the perinatal period, mainly in cesarean 
deliveries, and the prevalence of drugs that act on the nervous system. A cross-sectional 
Table 5. Distribution of most used drugs in delivery hospitalization according to age, according to the Anatomical Therapeutic Chemical 
(ATC; level 1)* classification system for pharmacological groups. 2015 Pelotas Births Cohort, Brazil.
Pharmacological groups*
13–19 years 20–30 years 31–45 years
n % 95%CI n % 95%CI n % 95%CI
N – Nervous System 591 29.1 27.2–31.1 2,202 30.2 29.0–31.1 1,481 31.5 30.1–32.8
M – Musculoskeletal system 303 15.0 13.4–16.5 1,006 13.8 12.9–14.5 579 12.3 11.4–13.3
A – Alimentay tract and metabolism 286 14.1 12.6–15.6 997 13.7 12.9–14.5 652 13.9 12.9–14.9
H – Hormonal preparations for systemic use 234 11.5 10.1–12.9 835 11.5 10.7–12.1 532 11.3 10.3–12.2
J – Anti-infective agents for systemic use 177 8.8 7.4–9.9 722 9.9 9.2–10.6 462 9.8 8.9–10.6
B – Blood and blood-forming organs 177 8.8 7.5–9.9 540 7.4 6.8–8.0 292 6.2 5.5–6.9
C – Cardiovascular System 106 5.2 4.2–6.2 481 6.6 6.2–7.3 376 8.0 7.1–8.7
D – Dermatologicals agents 59 2.9 2.1–3.6 175 2.4 2.1–2.8 114 2.4 2.0–2.8
R – Respiratory system 58 2.8 2.2–3.7 183 2.5 2.1–2.9 130 2.8 2.3–3.3
G – Genitourinary system and sex hormones 33 1.6 1.0–2.1 108 1.5 1.2–1.7 54 1.2 0.8–1.4
Others 3 0.2 39 0.5 28 0.6
Total 2,027 100 7,288 100 4,700 100
* World Health Organization, Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2014. Oslo; 
2014 [cited 2016 Mar 15]. Available from: whocc.no/atc_ddd_index/
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study carried out in four maternity hospitals of Belo Horizonte also reported extensive use 
of drugs in the immediate postpartum period, with 96% of women being given some form of 
drug1. Another study, carried out with 24 recent mothers in a maternity hospital of Ceará, 
showed the use of drugs in the immediate postpartum period in 63% of recent mothers and 
associated this use to cesarean delivery11.
The mean number of drugs used was higher in SUS hospitalizations, both in prepartum/during 
delivery and postpartum periods, inconsistently with the findings of Perini et al.8, which 
showed higher mean number of drugs in private hospitals in both periods. It is important 
to consider that the mean number of drugs in our study was higher in medical school 
hospitals, whose hospitalizations are mainly by the SUS. Drug use in these hospitals is 
higher probably because of the complexity of care, since they are the only ones in the city 
that have NICU. On the other hand, analysis of delivery type in relation to hospital type 
shows that the exclusively SUS medical school hospital conducts more vaginal deliveries 
than cesarean deliveries, while exclusively private and health insurance hospitals conduct 
more cesarean deliveries than vaginal deliveries. This reflects reality, because women who 
have health insurance or who intend to have private delivery usually schedule it to the 
most convenient date.
Cesarean delivery and epidural anesthesia are pointed out as the main factors associated 
with high consumption of drugs in the perinatal period8,11, which was also observed in our 
study, especially for drugs that act on the cardiovascular and respiratory systems, showing 
higher exposure to drugs and consequently higher risk to the safety of the mother and 
the baby. Metaraminol was only used in women who underwent caesarean delivery and, 
consequently, received spinal anesthesia. Metaraminol is a sympathomimetic agent used 
in the prophylaxis and treatment of hypotension in women who have cesarean delivery17.
On the other hand, women who had vaginal delivery were given more drugs that act on 
the blood and hematopoietic system than those who had cesarean delivery. Ferrous sulfate 
was the most used drug in this class, especially by younger mothers, who have a higher risk 
of developing anemia in gestation18, because they are in growth phase19. Dermatological 
drugs and those that act on the musculoskeletal system and hormonal preparations, which 
are generally safer in the perinatal period, due to presenting lower risk of serious adverse 
reactions and to being eliminated in breast milk20,21, were also among the most used when 
vaginal delivery was conducted. Thus, the drugs most used in cesarean delivery, such as 
bupivacaine and morphine, represent higher risk for the mother and the baby3,22, which 
points to one more harmful exposure in cesarean delivery.
A concerning fact as to the use of drugs in the perinatal period is that mothers are initiating 
breastfeeding, and they can interfere with milk production or cause unwanted effects on 
babies. Bupivacaine, medicine of the nervous system most used in this study, can interfere 
both beneficially and deleteriously with breastfeeding; however, there is lack of evidence, 
because the results are very inconsistent due to the via and form of administration, doses, 
time of use, etc. For example, in a randomized clinical trial conducted by Jolly et al., 
additional use of bupivacaine caused greater comfort during breastfeeding23. The use of 
morphine, in turn, can delay the initiation of breastfeeding and even cause child drowsiness, 
central nervous system depression, and even death. Even so, if the use of opiates is necessary 
for pain control, morphine in low doses is preferable in relation to the others24. Newborns 
seem to be particularly sensitive to the effects of narcotic analgesics, even in small doses25.
There are reports of episodes of cyanosis in the baby after the use of dipyrone (metamizole) 
by the breastfeeding mother. Dipyrone (metamizole) and its metabolites reach high 
concentrations in breast milk, remaining for up to 48 hours. It is recommended the use 
of other non-steroidal analgesic that is safer, or that the mother does not breastfeed for 
48 hours after using the drug26,27.
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Oxytocin appears as a medication widely used in this study, being widely used during 
childbirth. It is a hormone released during breastfeeding that seems to have tranquilizing 
effect on the mother20; however, the administration of exogenous oxytocin to mothers with 
difficulty in breast-feeding showed no beneficial effect on the success of lactation or on the 
treatment of breast engorgement. It seems to have no effect on the child. On the other hand, 
several studies suggest that oxytocin administered during delivery can negatively affect 
breastfeeding, possibly reducing the suction behavior in the newborn28–30. A study pointed 
out that all rhythmic reflexes, the antigravity reflex, and the primitive neonatal reflexes 
were inhibited by the administration of oxytocin during delivery, an effect unrelated to 
dose, which could also detrimental to breastfeeding31,32.
Among the medicines that act on the musculoskeletal system, diclofenac was the most 
widely used. Despite being widely used as post-cesarean delivery analgesic, there are few 
data on the excretion of this drug in breast milk, with most authors considering its use 
acceptable during breastfeeding33. Diclofenac has proven effective to reduce the dose of 
opioids in postpartum analgesia, with no important adverse reactions, such as bleeding 
or uterine atonia33.
The longer the length of hospital stay, the greater was the number of drugs used. This leads 
us to think that mothers who were hospitalized more days probably had postpartum 
complications or are women with more co-morbidities, requiring more monitoring. On the 
other hand, it was observed that a significant number of women (15%) had only one day 
of hospitalization. According to the Brazilian Ministry of Health (MS), there is no official 
definition about postpartum length of hospital stay, with only one reference in Ordinance 
1,016 noting that discharges should not be given before 48 hours34. The American Academy 
of Pediatrics (AAP), and the American College of Obstetrics and Gynecology (ACOG) define 
as early discharge that which occurs in the first 48 hours after delivery and as very early 
discharge that which occurs within the first 24 hours. They recommend 48 hours as mean 
time of hospitalization for non-complicated vaginal delivery and 96 hours for cesarean 
delivery35. This study found that 35% of mothers had early discharge and 15% had very 
early discharge, which puts at risk the health of both the mother and the baby. Analysis 
of hospitalization days in relation to hospitalization type (SUS, private health care, or 
health insurance) shows that women who had private or health insurance hospitalization 
stayed fewer days in the hospital than women who had SUS hospitalization, which reflects 
the following of the guidelines of the Ministry of Health by public hospitals and not by 
private hospitals.
A theoretical limitation of the study could be its conduct period, from June to October, 
very cold months in the city. However, a previous study8 showed no seasonality in the 
use of medicines in the perinatal period and highlights that it enables conducting such 
researches in short periods of time, saving time and money. Another limitation could be 
that the sample was a sub-sample of the 2015 Pelotas births cohort, which could have 
different characteristics. However, after analysis (not shown in the results because it 
was performed only for comparative purposes) it was shown that the sociodemographic 
characteristics of the mothers participating in this study are similar to those of the other 
mothers of the cohort.
This study found high drug consumption in the delivery hospitalization period, and the 
main factors were cesarean delivery and epidural anesthesia. The most used therapeutic 
group was that of drugs that act on the nervous system.
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